Publications & Reports

Nonnucleoside reverse transcriptase inhibitors reduce HIV-1 virus production from latently infected resting CD4+ T cells following latency reversal.

Zerbato JM, Tachedjian G, Sluis-Cremer N

Abstract

Therapeutic strategies that target the latent HIV-1 reservoir in resting CD4+ T cells of infected-individuals are always administered in the presence of combination antiretroviral therapy. Using a primary cell of HIV-1 latency, we evaluated whether different antiviral drug classes affected latency reversal (as assessed by extracellular virus production) by anti-CD3/CD28 monoclonal antibodies or by bryostatin 1. We found that the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine significantly decreased HIV-1 production by ≥ 1 log.

Link to publisher’s web site

Publication

  • Journal: Antimicrobial Agents and Chemotherapy
  • Published: 23/02/2017
  • Volume: 61
  • Issue: 3
  • Pagination: e01736-16

Author

Health Issue

Download